CASE CONTROL STUDY OF LEVETIRACETAM VS. FOSPHENYTOIN FOR SEIZURE PROPHYLAXIS IN CHILDREN RECEIVING BUSULFAN (BU) FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

被引：0
|
作者：
Skeens, M. A.
Soni, S.
Pai, V
Bajwa, R.
Pietryga, D.
Gross, T.
Termuhlen, A.
机构：
[1] Nationwide Childrens Hosp, Columbus, OH USA
[2] Ohio State Univ, Columbus, OH 43210 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2009.12.135
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
105
引用
收藏
页码：S195 / S195
页数：1
相关论文
共 50 条
  • [41] Unrelated donor hematopoietic stem cell transplantation (HSCT) in children with acute leukemia: Risks and benefits of umbilical cord blood (CB) vs. bone marrow (BM).
    Rubinstein, P
    Eapen, M
    Stevens, C
    Kurtzberg, J
    Scaradavou, A
    Klein, J
    Horowitz, M
    Wagner, J
    BLOOD, 2005, 106 (11) : 92A - 92A
  • [42] A combination of heparin, ursodiol and glutamine prophylaxis for hepatic venoocclusive disease (VOD) after hematopoietic stem cell transplantation (HSCT) in children.
    Goyal, M
    Sahdev, I
    Vlachos, A
    Focazio, B
    Lipton, JM
    BLOOD, 2002, 100 (11) : 414A - 414A
  • [43] Reiterated Therapeutic Drug Monitoring (TDM) Dosing to Significantly Improve the Control of Exposure to IV Busulfan in Infants and Older Children Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)
    Amin, Alexandre
    Bourget, Philippe
    Neven, Benedicte
    Fremond, Marie-Louise
    Castelle, Martin
    Elkaim, Elodie
    Cros, Guilhem
    Moshous, Despina
    Touzot, Fabien
    Lalli, Alexandre
    Petain, Aurelie
    Nguyen, Laurent
    Blanche, Stephane
    BLOOD, 2015, 126 (23)
  • [44] New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning
    Poinsignon, Vianney
    Faivre, Laura
    Nguyen, Laurent
    Neven, Benedicte
    Broutin, Sophie
    Moshous, Despina
    Bourget, Philippe
    Dufour, Christelle
    Dalle, Jean-Hugues
    Galambrun, Claire
    Devictor, Benedicte
    Kemmel, Veronique
    De Berranger, Eva
    Gandemer, Virginie
    Vannier, Jean Pierre
    Jubert, Charlotte
    Bondu, Sabrina
    Mir, Olivier
    Petain, Aurelie
    Vassal, Gilles
    Paci, Angelo
    PEDIATRIC BLOOD & CANCER, 2020, 67 (10)
  • [45] Busulfan / Melphalan / Bortezomib (Bu-Mel-Vet) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Zhong, Xiaobo
    Sterrenberg, Danielle
    Vesole, David H.
    BLOOD, 2013, 122 (21)
  • [46] Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation:: A case-control study
    Sangiolo, D
    Storer, B
    Nash, R
    Corey, L
    Davis, C
    Flowers, M
    Hackman, RC
    Boeckh, M
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (07) : 521 - 529
  • [47] Allogeneic hematopoietic stem cell transplantation (HSCT) without prophylaxis of Graft-vs-Host disease (GVHD) - Adoptive cellular immunotherapy of leukemia.
    Duerst, RE
    Zwetsch, L
    Senf, E
    Abboud, CN
    Liesveld, JL
    BLOOD, 1998, 92 (10) : 342B - 342B
  • [48] Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation
    Gokcebay, D. Gurlek
    Azik, F.
    Ozbek, N.
    Isik, P.
    Avci, Z.
    Tavil, B.
    Kara, A.
    Tunc, B.
    PEDIATRIC TRANSPLANTATION, 2015, 19 (03) : 307 - 315
  • [49] Association of Cth Genetic Variant with Veno-Occlusive Disease in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation.
    Huezo-Diaz, Patricia
    Uppungunduri, Chakradhara Rao
    Tyagi, Anuj Kumar
    Rezgui, Mohamed Aziz
    Gumy-Pause, Fabienne
    Duval, Michel
    Bittencourt, Henrique
    Krajinovic, Maja
    Ansari, Marc
    BLOOD, 2012, 120 (21)
  • [50] Busulfex® cyclophosphamide, thymoglobulin® (BU/CY/Thymo) as preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in children with non-malignant disorders (NMD)
    Gross, TG
    Orchard, P
    Termublen, AM
    Baker, KS
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 128 - 129
12345